Zhejiang Xinguang Pharmaceutical Co., Ltd. (SHE:300519)

SHE:300519 Revenue

Zhejiang Xinguang Pharmaceutical had revenue of 68.36M CNY in the quarter ending September 30, 2026, with 5.70% growth. This brings the company's total for the last twelve months to 270.70M, up 5.30% year-over-year. In the year 2025, Zhejiang Xinguang Pharmaceutical had annual revenue of 265.36M, down -0.86%. That makes Zhejiang Xinguang Pharmaceutical the 29,425th largest company in the world by revenue and 4,918th in China.

• Revenue (ttm): 270.70M
• Revenue Growth: +5.30%
• P/S Ratio: 8.54
• Revenue / Employee: 876.05K
• Employees: 309
• Market Cap: 2.31B

Revenue Chart

Chart

Chart

Revenue by Segment

Chart

• The Radix Astragali Lives The Arteries to Drink 191.73M 72.3%
• American Ginseng Oral Liquid 45.87M 17.3%
• Shenjin Dan Capsule 22.54M 8.5%
• Other Products 4.98M 1.9%
• Unallocated Other Business 230.76K 0.1%

Fiscal year ended Dec 31, 2025 See the full SHE:300519 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	265.36M	-2.30M	-0.86%
Dec 31, 2024	267.66M	-2.74M	-1.01%
Dec 31, 2023	270.40M	-81.09M	-23.07%
Jan 1, 2023	351.49M	30.61M	9.54%
Jan 1, 2022	320.88M	37.80M	13.35%

Data Source: S&P Global Market Intelligence Last updated: Oct 22, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 12, 2026

Data Sources Report a data error